RICHARD J. STEVENS, MD MEMORIAL LECTURE
RESEARCH DAY | INVITED LECTURER
MARCH 30, 2018 at 11:30 AM • HARLESS AUDITORIUM
ZIJIAN XIE, Ph.D.
Director, Marshall Institute for Interdisciplinary Research (MIIR)
Marshall University
“The Discovery of Na/K-ATPase as a Potential Drug Target for Multiple Human Diseases”
Learning Objectives:
Discover 1) How is Na/K-ATPase engaged in cellular activity other than pumping ions across cell
membrane; 2) the importance of non-pumping functions of Na/K-ATPase in animal physiology and
disease progression; 3) what can we do to translate this new discovery into practice that will
improve human health.
No Conflicts Indicated
Dr. Zijian Xie was named director of the Marshall Institute for Interdisciplinary Research in
November 2013.
His laboratory is internationally recognized for its groundbreaking work to understand the behavior
of cellular pathways and their relationship to cancer, renal disease and cardiac failure.
Xie holds international patents and patent applications on seven medical inventions resulting from
his research. He has served as principal investigator, project leader or co-investigator on
National Institutes of Health-funded projects totaling more than $10 million, and has established
active international collaborations with total funding of more than $1 million. He has been
involved with the creation of two spin-off companies from his research.
He is the author or co-author of more than 100 articles published in scientific journals, has
authored a number of book chapters and has been invited to give numerous presentations as part of
national and international conferences, symposia, seminars and visiting professorships. He serves
as a regular member of NIH study sections and has chaired and co-organized several international
symposia.
Dr. Xie came to Marshall from the faculty of the University of Toledo’s College of Medicine, where
he was a professor of physiology, pharmacology and medicine, and served as the co-director of the
M.D./Ph.D. program.
He earned a bachelor’s degree from the Nanjing College of Pharmacy in Nanjing, China, in 1982, a
master’s degree in toxicology at the Chinese Academy of Medical Sciences in Beijing in 1984 and
adoctorate in pharmacology at the Medical College of Ohio (now University of Toledo) in 1990.